In Section A, contributors will receive unique doses and schedules of oral ABBV-744 pill to identify Safe and sound dosing program. Extra contributors will likely be enrolled within the identified monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 will be provided as "insert-on" therapy. In https://abbal776zkv9.howeweb.com/profile